Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Visceral Leishmaniasis Market Growth Potential: How Will Market Size Change Through 2030?
The market for visceral leishmaniasis demonstrated significant expansion recently, projecting a rise from $1.06 billion in 2025 to $1.12 billion in 2026, reflecting a compound annual growth rate of 5.9%. Factors contributing to this historical growth include an increase in the prevalence of endemic diseases, heightened public health awareness campaigns, the accessibility of established antiparasitic therapies, the proliferation of hospital-based treatment initiatives, and support from international health organizations.
The market for visceral leishmaniasis is projected for substantial expansion in the coming years, anticipated to reach $1.39 billion by 2030, driven by a compound annual growth rate of 5.5%. This projected expansion is fueled by several key factors, including heightened investments in innovative therapeutic approaches, an intensified focus on developing vaccines and immunotherapies, broader implementation of molecular diagnostic tools, augmented government financial support aimed at disease eradication efforts, and improved access to treatment within regions where the disease is prevalent. Emerging trends expected to shape this market during the forecast period encompass the increasing acceptance of sophisticated diagnostic methods, a rise in the utilization of combined drug treatment regimens, a greater emphasis on identifying the disease in its early stages, the proliferation of public health screening initiatives, and greater endeavors to enhance treatment accessibility.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp
Visceral Leishmaniasis Market Opportunity Drivers: What Is Creating New Revenue Potential?
An escalating prevalence of malnutrition is anticipated to be a significant driver for the expansion of the visceral leishmaniasis market. Malnutrition, characterized by insufficient or unbalanced consumption of nutrients essential for proper bodily functions, stems largely from food insecurity. This lack of access to adequate and nutritious food results in undernourishment and deficiencies in essential micronutrients, ultimately compromising the body’s immune defenses. A weakened immune system, a direct consequence of malnutrition, heightens susceptibility to infections like visceral leishmaniasis, as the body’s natural defenses are diminished. This compromised immune status increases the likelihood of developing severe forms of the disease and experiencing related complications. Illustrating this global challenge, data from the United Nations Children’s Fund (UNICEF) indicated that approximately 733 million individuals worldwide faced undernourishment in the year 2023 as of July 2024. Consequently, the upward trend in malnutrition is directly contributing to the growth observed in the visceral leishmaniasis market.
Visceral Leishmaniasis Market Categorization By Product Type And Application
The visceral leishmaniasis market covered in this report is segmented –
1) By Treatment: Antiparasitic, Antifungal, Other Treatments
2) By Diagnosis Method: Serological Tests, Molecular Tests, Microscopy, Culture Methods
3) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Antiparasitic: Pentavalent Antimonials, Miltefosine, Paromomycin, Sitamaquine, Combination Therapy
2) By Antifungal: Amphotericin B, Liposomal Amphotericin B (AmBisome), Azoles, Echinocandins, Polyenes
3) By Other Treatments: Immunotherapy, Monoclonal Antibodies, Vaccine-Based Approaches, Photodynamic Therapy, Gene Therapy
Visceral Leishmaniasis Market Innovation Trends Driving Future Development
Within the visceral leishmaniasis market, key players are dedicating efforts towards refining therapeutic strategies, specifically through the creation of novel antiparasitic agents aimed at boosting treatment effectiveness and broadening patient access, especially in areas where the disease is prevalent. These antiparasitic drugs function by targeting the metabolic processes and life cycles of parasites, thereby impeding their development, proliferation, or viability inside a host organism. Illustrating this, in February of 2024, Zydus Lifesciences Limited, a pharmaceutical entity headquartered in India, secured prequalification status from the World Health Organization (WHO) for both the active pharmaceutical ingredient and the finished dosage form of miltefosine, a medication utilized for leishmaniasis, also known as kala-azar. Miltefosine operates as an orally administered antiparasitic compound, effective by compromising the parasite’s cellular membrane and disrupting its metabolic pathways, ultimately resulting in cell demise. Furthermore, it hinders parasitic proliferation and persistence, establishing itself as a viable and convenient oral therapeutic choice for visceral leishmaniasis and kala azar.
Visceral Leishmaniasis Market Company Landscape And Strategic Competition
Major companies operating in the visceral leishmaniasis market are Pfizer Inc., GSK plc, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd., Xellia Pharmaceuticals, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, Sanofi SA, Bharat Serums and Vaccines Limited, Emcure Pharmaceuticals Limited, Hetero Drugs Limited, Lupin Limited, Ipca Laboratories Limited, Intas Pharmaceuticals Limited, Macleods Pharmaceuticals Limited, Mankind Pharma Limited, Alembic Pharmaceuticals Limited
Access The Complete Visceral Leishmaniasis Market Report:
https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report
Visceral Leishmaniasis Market Regional Outlook: Where Are The Largest Opportunities Located?
North Americawas the largest region in the visceral leishmaniasis market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
